CME Case Study

A 56-Year-Old Female Presents With Lower Urinary Tract Symptoms. ... Does She Have OAB or Not?

Overactive bladder (OAB) affects 33 million adults in the US. Evaluation and management of lower urinary tract symptoms (LUTS), particularly OAB, can be challenging. This case study submission and faculty response highlight several key aspects in the evaluation and management of LUTS, particularly OAB. This representative case study exemplifies the need to exclude other conditions that may mimic OAB and identifies ancillary studies that may be useful in the evaluation of a patient with OAB.

Learning Objectives and Faculty

Step 1
Educational Objectives
At the conclusion of this activity, participants should be able to:
  • Recall the definition of OAB and recognize urgency as the cardinal symptom of OAB
  • Identify other medical conditions that may cause/mimic OAB
  • Discuss the role of routine and ancillary studies in the evaluation of OAB

Faculty
Pamela I. Ellsworth, MD, Program Chair
Associate Professor of Surgery
Division of Urology
The Warren Alpert School of Medicine of Brown University
Providence, RI

Stephen A. Brunton, MD, Program Co-Chair
Adjunct Clinical Professor
Department of Family Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Director of Faculty Development
Cabarrus Family Residency Program
Concord, NC

Alan J. Wein, MD, PhD (Hon), Program Co-Chair
Professor and Chair
Department of Surgery
Division of Urology
University of Pennsylvania School of Medicine
Chief
Division of Urology
University of Pennsylvania Health System
Philadelphia, PA

Faculty Disclosures
In accordance with the disclosure policy of the Warren Alpert Medical School of Brown University as well as standards set forth by the Accreditation Council for Continuing Medical Education, all speakers and individuals in a position to control the content of a CME activity are required to disclose relevant financial relationships with commercial interests (within the past 12 months). Disclosures of this activity’s speakers and planning committee have been reviewed and all identified conflicts of interest, if applicable, have been resolved.

Pamela Ellsworth, MD, is a consultant for Pfizer Inc and Allergan, Inc., has participated in speaker training meetings for Novartis AG, and is a speaker for Pfizer Inc.
Stephen A. Brunton, MD, has no financial interests to disclose.
Alan J. Wein, MD, PhD (Hon), is a consultant for Pfizer Inc, Astellas Pharma US, Inc., and  Novartis AG.